AAP
MRM

Arax Advisory Partners’s MEDIROM Healthcare Technologies MRM Stock Holding History

Arax Advisory Partners’s Portfolio MRM Stock Details MRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$309 Buy
+300
New +$337 ﹤0.01% 5057

Other funds holding MRM

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Arax Advisory Partners's MRM Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in MEDIROM Healthcare Technologies (MRM) in Q2 2026: 300 shares worth $309. The stake represents ﹤0.01% of the portfolio and ranks #5057 among its holdings.

8 funds tracked by Wall St. Rank hold MRM as of Q2 2026.

  • Arax Advisory Partners held 300 shares of MEDIROM Healthcare Technologies worth $309 as of Q2 2026.
  • MEDIROM Healthcare Technologies was a new Arax Advisory Partners position in Q2 2026.
  • MEDIROM Healthcare Technologies made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5057 holding.
  • 8 funds tracked by Wall St. Rank held MEDIROM Healthcare Technologies as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.